<DOC>
	<DOCNO>NCT01732939</DOCNO>
	<brief_summary>The study purpose observe neoadjuvant chemotherapy regimens well invasive breast cancer . The neoadjuvant chemotherapy regimen sustain anthracyclines plus taxanes anthracyclines plus taxanes vinorelbine plus cisplatinum .</brief_summary>
	<brief_title>Phase II Study Neoadjuvant Chemotherapy Regimen Choice Breast Cancer</brief_title>
	<detailed_description>The investigator hope get preliminary result breast cancer patient give different neoadjuvant chemothetapy regimen . The patient randomize two chemotherapy regimen . One anthracyclines plus taxanes 6-8 cycle , anthracyclines plus taxanes 3-4 cycle , switch tovinorelbine plus cisplatinum 3-4 cycle .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Diagnosis invasive ductal lobular breast cancer . Previously untreated ( chemotherapy hormonal therapy radiation therapy ) invasive breast cancer . antiHer2 therapy HER2 positive ( defined 3+ IHC FISH positive ) Performance Status ECOG &lt; 2 Age &gt; 18 year Tumor &gt; 2.0 cm MRI and/or sonographic clinical exam measurements.or Karnofsky &gt; 50 % Lab test : Absolute neutrophil count &gt; 1,500/mm3 Total Bilirubin ≤ 2×ULN AST ALT ≤ 2.5×ULN serum creatinine ≤ 1.5×ULN Pregnant breast feeding patient exclude stage Ⅳ breast cancer History nonbreast malignancy within 5 year prior study entry , except follow : carcinoma situ cervix , carcinoma situ colon , melanoma situ , basal cell squamous cell carcinoma skin uncontrolled cardiac disease Active infection chronic infection require chronic suppressive antibiotic History hypersensitivity reaction investigate drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>